Comorbidities and Treatment Outcomes in Multidrug Resistant Tuberculosis: a Systematic Review and Meta-analysis

Overview

Journal Sci Rep

Specialty Science

Date 2018 Mar 23

PMID 29563561

Citations 38

Authors

Joel Philip Samuels

Aashna Sood

Jonathon R Campbell

Faiz Ahmad Khan

James Cameron Johnston

Affiliations

Soon will be listed here.

Abstract

Little is known about the impact of comorbidities on multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) treatment outcomes. We aimed to examine the effect of human immunodeficiency virus (HIV), diabetes, chronic kidney disease (CKD), alcohol misuse, and smoking on MDR/XDRTB treatment outcomes. We searched MEDLINE, EMBASE, Cochrane Central Registrar and Cochrane Database of Systematic Reviews as per PRISMA guidelines. Eligible studies were identified and treatment outcome data were extracted. We performed a meta-analysis to generate a pooled relative risk (RR) for unsuccessful outcome in MDR/XDRTB treatment by co-morbidity. From 2457 studies identified, 48 reported on 18,257 participants, which were included in the final analysis. Median study population was 235 (range 60-1768). Pooled RR of unsuccessful outcome was higher in people living with HIV (RR = 1.41 [95%CI: 1.15-1.73]) and in people with alcohol misuse (RR = 1.45 [95%CI: 1.21-1.74]). Outcomes were similar in people with diabetes or in people that smoked. Data was insufficient to examine outcomes in exclusive XDRTB or CKD cohorts. In this systematic review and meta-analysis, alcohol misuse and HIV were associated with higher pooled OR of an unsuccessful outcome in MDR/XDRTB treatment. Further research is required to understand the role of comorbidities in driving unsuccessful treatment outcomes.

Citing Articles

Comorbidities and Treatment Outcomes in Patients Diagnosed with Drug-Resistant Tuberculosis in Rural Eastern Cape Province, South Africa.

Hosu M, Faye L, Apalata T Diseases. 2024; 12(11).

PMID: 39589970 PMC: 11593127. DOI: 10.3390/diseases12110296.

HIV co-infection increases the risk of post-tuberculosis mortality among persons who initiated treatment for drug-resistant tuberculosis.

Salindri A, Kipiani M, Lomtadze N, Tukvadze N, Avaliani Z, Blumberg H Sci Rep. 2024; 14(1):23834.

PMID: 39394335 PMC: 11470076. DOI: 10.1038/s41598-024-68605-2.

Mitochondrial Transplantation Promotes Protective Effector and Memory CD4 T Cell Response During Mycobacterium Tuberculosis Infection and Diminishes Exhaustion and Senescence in Elderly CD4 T cells.

Headley C, Gautam S, Olmo-Fontanez A, Garcia-Vilanova A, Dwivedi V, Schami A Adv Sci (Weinh). 2024; 11(36):e2401077.

PMID: 39039808 PMC: 11423092. DOI: 10.1002/advs.202401077.

Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea.

Son E, Choi H, Mok J, Kang Y, Jeong D, Jeon D Korean J Intern Med. 2024; 39(4):640-649.

PMID: 38910510 PMC: 11236803. DOI: 10.3904/kjim.2024.029.

Community-based directly observed therapy is effective and results in better treatment outcomes for patients with multi-drug resistant tuberculosis in Uganda.

Makabayi-Mugabe R, Musaazi J, Zawedde-Muyanja S, Kizito E, Fatta K, Namwanje-Kaweesi H BMC Health Serv Res. 2023; 23(1):1248.

PMID: 37957610 PMC: 10644403. DOI: 10.1186/s12913-023-10120-7.

References

Brust J, Gandhi N, Carrara H, Osburn G, Padayatchi N . High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010; 14(4):413-9. PMC: 3005763. View

Ettehad D, Schaaf H, Seddon J, Cooke G, Ford N . Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(6):449-56. DOI: 10.1016/S1473-3099(12)70033-6. View

ODonnell M, Padayatchi N, Master I, Osburn G, Horsburgh C . Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis. 2009; 13(7):855-61. PMC: 2855970. View

Kvasnovsky C, Cegielski J, Erasmus R, Siwisa N, Thomas K, van der Walt M . Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011; 57(2):146-52. DOI: 10.1097/QAI.0b013e31821190a3. View

Seung K, Omatayo D, Keshavjee S, Furin J, Farmer P, Satti H . Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009; 4(9):e7186. PMC: 2746313. DOI: 10.1371/journal.pone.0007186. View

Charles M, Vilbrun S, Koenig S, Hashiguchi L, Mabou M, Ocheretina O . Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. Am J Trop Med Hyg. 2014; 91(4):715-21. PMC: 4183393. DOI: 10.4269/ajtmh.14-0161. View

Farley J, Ram M, Pan W, Waldman S, Cassell G, Chaisson R . Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One. 2011; 6(7):e20436. PMC: 3142109. DOI: 10.1371/journal.pone.0020436. View

Kim H, Hwang S, Kim H, Lee S, Yoo C, Kim Y . Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007; 45(10):1290-5. DOI: 10.1086/522537. View

Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G, Van den Bergh R . Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action. 2015; 4(Suppl 2):S47-53. PMC: 4547513. DOI: 10.5588/pha.14.0041. View

10.

Isaakidis P, Casas E, Das M, Tseretopoulou X, Ntzani E, Ford N . Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2015; 19(8):969-78. DOI: 10.5588/ijtld.15.0123. View

11.

Laserson K, Thorpe L, Leimane V, Weyer K, Mitnick C, Riekstina V . Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005; 9(6):640-5. View

12.

Kwak N, Kim H, Yoo C, Kim Y, Han S, Yim J . Changes in treatment outcomes of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2015; 19(5):525-30. DOI: 10.5588/ijtld.14.0739. View

13.

Slama K, Chiang C, Enarson D, Hassmiller K, Fanning A, Gupta P . Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc Lung Dis. 2007; 11(10):1049-61. View

14.

Jain K, Desai M, Solanki R, Dikshit R . Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2014; 5(2):145-9. PMC: 4008910. DOI: 10.4103/0976-500X.130062. View

15.

Johnston J, Shahidi N, Sadatsafavi M, FitzGerald J . Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009; 4(9):e6914. PMC: 2735675. DOI: 10.1371/journal.pone.0006914. View

16.

Ahmad N, Javaid A, Basit A, Afridi A, Khan M, Ahmad I . Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015; 19(9):1109-14, i-ii. DOI: 10.5588/ijtld.15.0167. View

17.

Dolgusev O, Obevzenco N, Padalco O, Pankrushev S, Ramsay A, Van den Bergh R . Pattern of primary tuberculosis drug resistance and associated treatment outcomes in Transnistria, Moldova. Public Health Action. 2015; 4(Suppl 2):S64-6. PMC: 4547515. DOI: 10.5588/pha.14.0043. View

18.

Khaliaukin A, Kumar A, Skrahina A, Hurevich H, Rusovich V, Gadoev J . Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus. Public Health Action. 2015; 4(Suppl 2):S24-8. PMC: 4547519. DOI: 10.5588/pha.14.0042. View

19.

Magee M, Kempker R, Kipiani M, Tukvadze N, Howards P, Narayan K . Diabetes mellitus, smoking status, and rate of sputum culture conversion in patients with multidrug-resistant tuberculosis: a cohort study from the country of Georgia. PLoS One. 2014; 9(4):e94890. PMC: 3988137. DOI: 10.1371/journal.pone.0094890. View

20.

Phuong N, Nhung N, Hoa N, Thuy H, Takarinda K, Tayler-Smith K . Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public Health Action. 2016; 6(1):25-31. PMC: 4809724. DOI: 10.5588/pha.15.0068. View